130,017 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 130,017 shares of the company's stock, valued at approximately $2,395,000. Massachusetts Financial Services Co. MA owned about 0.06% of Hims & Hers Health at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC increased its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health in the second quarter worth $111,000. Finally, Amalgamated Bank increased its position in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after purchasing an additional 2,354 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,609 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.60, for a total transaction of $169,491.40. Following the completion of the sale, the chief financial officer now owns 181,469 shares in the company, valued at $2,649,447.40. The trade was a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,345 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the sale, the insider now owns 159,796 shares of the company's stock, valued at approximately $2,341,011.40. This represents a 1.45 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,153,519 shares of company stock valued at $24,486,721. 17.71% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. TD Cowen reiterated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler reiterated a "neutral" rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Imperial Capital cut Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research report on Friday, August 9th. Finally, Bank of America cut Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $20.71.

Hims & Hers Health Stock Down 1.1 %

HIMS traded down $0.33 during trading on Wednesday, hitting $30.35. The company's stock had a trading volume of 24,682,978 shares, compared to its average volume of 9,806,751. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02. The stock's fifty day moving average price is $21.14 and its 200-day moving average price is $19.57. The firm has a market capitalization of $6.63 billion, a P/E ratio of 68.96 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the firm earned ($0.04) earnings per share. The company's revenue was up 77.1% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.